CA2153228A1 - Inhibiteurs peptidiques de l'adhesion cellulaire - Google Patents

Inhibiteurs peptidiques de l'adhesion cellulaire

Info

Publication number
CA2153228A1
CA2153228A1 CA002153228A CA2153228A CA2153228A1 CA 2153228 A1 CA2153228 A1 CA 2153228A1 CA 002153228 A CA002153228 A CA 002153228A CA 2153228 A CA2153228 A CA 2153228A CA 2153228 A1 CA2153228 A1 CA 2153228A1
Authority
CA
Canada
Prior art keywords
compound
asp
arg
phe
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153228A
Other languages
English (en)
Inventor
Shiu-Lan Ng Chiang
Pina M. Cardarelli
Thomas J. Lobl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2153228A1 publication Critical patent/CA2153228A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002153228A 1993-01-08 1994-01-07 Inhibiteurs peptidiques de l'adhesion cellulaire Abandoned CA2153228A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US177393A 1993-01-08 1993-01-08
US08/001,773 1993-01-08
CN94115995A CN1114961A (zh) 1993-01-08 1994-07-11 细胞粘连肽抑制剂

Publications (1)

Publication Number Publication Date
CA2153228A1 true CA2153228A1 (fr) 1994-07-21

Family

ID=37075853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153228A Abandoned CA2153228A1 (fr) 1993-01-08 1994-01-07 Inhibiteurs peptidiques de l'adhesion cellulaire

Country Status (6)

Country Link
EP (1) EP0677060A1 (fr)
JP (1) JPH08505628A (fr)
CN (1) CN1114961A (fr)
CA (1) CA2153228A1 (fr)
SG (1) SG52262A1 (fr)
WO (1) WO1994015958A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126748T3 (es) * 1993-03-29 1999-04-01 Du Pont Merck Pharma Proceso y compuestos intermedios para la preparacion de inhibidores de la glicoproteina plaquetaria ii b/iii a.
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO1996040781A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
EP0842195A1 (fr) * 1995-07-06 1998-05-20 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
DK0914605T3 (da) 1996-07-25 2007-09-10 Biogen Idec Inc Molekylemodel for VLA-4-inhibitorer
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
AU6895598A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO1999025731A1 (fr) 1997-11-13 1999-05-27 Toray Industries, Inc. Peptides cycliques et leur utilisation medicinale
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
YU75500A (sh) 1998-05-28 2002-12-10 Biogen Inc. NOVI VLA-4 INHIBITORI oMePUPA-V
WO1999065944A1 (fr) * 1998-06-15 1999-12-23 Ixsys Incorporated INHIBITEURS PEPTIDIQUES DE αVβ3 ET αVβ¿5?
AU757873B2 (en) 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200200070A (et) 1999-08-13 2003-04-15 Biogen, Inc. Raku adhesiooni inhibiitorid
JP2003517023A (ja) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1477482B1 (fr) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Nouveau derive de phenylalanine
US7570871B2 (en) 2002-11-12 2009-08-04 Koninklijke Philips Electronics N.V. Continue recording channel feature for personal video recorder
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
EP1700850B1 (fr) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Derivé phenylalanine
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP2510941A3 (fr) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
JP2013523768A (ja) 2010-04-02 2013-06-17 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｒｆアミド関連ペプチドおよびその方法
WO2018140510A1 (fr) 2017-01-25 2018-08-02 Biogen Ma Inc. Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
CN110423265A (zh) * 2019-04-03 2019-11-08 中国药科大学 一种环肽类trf2抑制剂的制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
WO1992008476A1 (fr) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides inhibant la liaison plaquettaire de molecules d'ashesion
CA2078817A1 (fr) * 1991-10-18 1993-04-19 Beat A. Imhof Anticorps anti-.alpha.6-integrine
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val

Also Published As

Publication number Publication date
EP0677060A1 (fr) 1995-10-18
SG52262A1 (en) 1998-09-28
WO1994015958A3 (fr) 1994-09-29
CN1114961A (zh) 1996-01-17
WO1994015958A2 (fr) 1994-07-21
JPH08505628A (ja) 1996-06-18

Similar Documents

Publication Publication Date Title
WO1994015958A2 (fr) Inhibiteurs peptidiques de l'adhesion cellulaire
US5192746A (en) Cyclic cell adhesion modulation compounds
US5510332A (en) Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
Barker et al. Cyclic RGD peptide analogs as antiplatelet antithrombotics
JP3248584B2 (ja) フィブロネクチン接着抑制剤
CA2660183C (fr) Peptides ayant une activite pharmacologique pour le traitement de troubles associes a la migration de cellules alterees, tels que le cancer
WO1996040781A1 (fr) INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
EP0478101B1 (fr) Utilisation thérapeutique des peptides ayant une activité de type thrombospondine
AU602483B2 (en) Immunoregulatory peptides
JP2006028195A (ja) フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤
JPH11508583A (ja) ペプチド系のフィブロネクチン阻害薬
BG65065B1 (bg) Пептидни антиангиогенни лекарствени средства
AU641366B2 (en) Peptide compounds
EP0514721B1 (fr) Peptides ayant une activité de type thrombospondine et leur utilisation thérapeutique
JPH02500517A (ja) ペプチド化合物
US5821329A (en) Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
US5721210A (en) Cyclic cell adhesion modulation compounds
US6333307B1 (en) Compounds and method for modulating neurite outgrowth
RU2163242C2 (ru) Циклогексапептиды, их смеси, способ их получения
US6239110B1 (en) Synthetic analogs of thrombospondin and therapeutic use thereof
US5648461A (en) Synthetic analogs of thrombospondin and therapeutic use thereof
NZ260946A (en) Peptide cell adhesion inhibitors, pharmaceutical compositions, and diagnosis of disease
JP2000503649A (ja) 抗血栓剤および使用法
US4330465A (en) Novel β-endorphin analogs
CA2149783A1 (fr) Nouveaux peptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead